X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (53) 53
index medicus (52) 52
male (38) 38
female (37) 37
oncology (36) 36
middle aged (34) 34
aged (32) 32
colorectal cancer (29) 29
cancer (28) 28
adult (27) 27
chemotherapy (26) 26
aged, 80 and over (23) 23
gastroenterology & hepatology (19) 19
prognosis (19) 19
survival (19) 19
microsatellite instability (18) 18
mutation (15) 15
colorectal neoplasms - genetics (14) 14
life sciences (14) 14
colorectal neoplasms - pathology (13) 13
oxaliplatin (13) 13
retrospective studies (12) 12
analysis (11) 11
metastasis (11) 11
treatment outcome (11) 11
tumors (11) 11
adenocarcinoma (10) 10
care and treatment (10) 10
cisplatin (10) 10
fluorouracil (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
carcinoma (9) 9
genetic aspects (9) 9
surgery (9) 9
young adult (9) 9
antineoplastic agents - therapeutic use (8) 8
colorectal-cancer (8) 8
gastroenterology and hepatology (8) 8
kaplan-meier estimate (8) 8
neoplasm metastasis (8) 8
research article (8) 8
abridged index medicus (7) 7
colorectal neoplasms - immunology (7) 7
disease-free survival (7) 7
neoplasm staging (7) 7
prognostic-factors (7) 7
research (7) 7
5-fluorouracil (6) 6
adenocarcinoma - drug therapy (6) 6
cancer research (6) 6
colon cancer (6) 6
diagnosis (6) 6
digestive system diseases (6) 6
genetics (6) 6
management (6) 6
metastases (6) 6
patient outcomes (6) 6
prospective studies (6) 6
proto-oncogene proteins b-raf - genetics (6) 6
adenocarcinoma - pathology (5) 5
article (5) 5
cancer therapies (5) 5
capecitabine (5) 5
cetuximab (5) 5
chemoradiation (5) 5
colorectal carcinoma (5) 5
deoxyribonucleic acid--dna (5) 5
expression (5) 5
france (5) 5
leucovorin (5) 5
lung-cancer (5) 5
medical prognosis (5) 5
medical research (5) 5
mortality (5) 5
neoplasms (5) 5
phase-iii trial (5) 5
proportional hazards models (5) 5
proto-oncogene proteins p21 - genetics (5) 5
radiation therapy (5) 5
survival analysis (5) 5
[sdv.can]life sciences [q-bio]/cancer (4) 4
adenocarcinoma - therapy (4) 4
adolescent (4) 4
apoptosis (4) 4
bevacizumab (4) 4
biology (4) 4
braf (4) 4
braf mutation (4) 4
colon-cancer (4) 4
colorectal neoplasms - drug therapy (4) 4
deoxycytidine - analogs & derivatives (4) 4
dna (4) 4
epidemiology (4) 4
fluorouracil - therapeutic use (4) 4
health aspects (4) 4
immunology (4) 4
lymphocytes (4) 4
medicine, experimental (4) 4
mesh: humans (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 04/2019, Volume 111, pp. 94 - 106
Journal Article
Immunity, ISSN 1074-7613, 03/2016, Volume 44, Issue 3, pp. 698 - 711
Journal Article
British Journal of Cancer, ISSN 0007-0920, 09/2015, Volume 113, Issue 7, pp. 989 - 995
Journal Article
by Schmidt, Manfred and Verhoeyen, Els and Gobbo, Emilie and Divers, Dominique and Oudrhiri, Noufissa and Griscelli, Frank and Bennaceur-Griscelli, Annelise and Klatzmann, David and Anguela, Xavier M and Sharma, Rajiv and Sharma, Rajiv and Li, Hojun and Li, Hojun and Haurigot, Virginia and Haurigot, Virginia and Haurigot, Virginia and Bhagwat, Anand and Bhagwat, Anand and Davidson, Robert and Davidson, Robert and Zhou, Shangzhen and Zhou, Shangzhen and Zhou, Shangzhen and Doyon, Yannick and Gregory, Philip D and Gregory, Philip D and Gregory, Philip D and Holmes, Michael C and Holmes, Michael C and Holmes, Michael C and High, Katherine A and Carbonaro, Denise and Shaw, Kit and Jin, Xiangyang and Geiger, Sabine and Mishra, Suparna and Cooper, Aaron and DeOliveira, Satiro and Sokolic, Rob and Candotti, Fabio and Carmo, Marlene and Arumugam, Paritha and Alonso-Ferrero, Maria and Schambach, Axel and Schambach, Axel and Baum, Christopher and Baum, Christopher and Baum, Christopher and Risma, Kimberly and Malik, Punam and Jordan, Michael and Rivat, Christine and Booth, Claire and Thrasher, Adrian and Whilding, Lynsey and Archibald, Kyra and Oberg, Daniel and Golan, Talia and Hubert, Ayala and Shemi, Amotz and Khvalevsky, Elina Zorde and Gabai-Malka, Racheli and Focht, Gili and Brunschwig, Zivia and Raskin, Stephen and Goldberg, Nahum and Ben-David, Eli and Peretz, Tamar and Eliakim, Rami and Dankur, Alan and Galun and Rachmur, Itzik and Domb, Avi and Kopelman, Yael and Hantz, Yael and Lahav, Mor and Arbel-Alon, Sagit and Dickson, George and Barkats, Martine and Daboussi, Fayza and Silva, Georges and Cedrone, Frederic and Epinat, Jean Charles and Juillerat, Alexandre and Valton, Julien and Montini, Eugenio and Biffi, Alessandra and Biffi, Alessandra and Calabria, Andrea and Calabria, Andrea and Biasco, Luca and Biasco, Luca and Cesani, Martina and Cesani, Martina and Benedicenti, Fabrizio and Benedicenti, Fabrizio and Plati, Tiziana and Leo, Simone and Zanetti, Gianluigi and Aiuti, Alessandro and ...
Human Gene Therapy, ISSN 1043-0342, 10/2012, Volume 23, Issue 10, pp. A1 - A173
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, pp. e100819 - e100819
Beclin 1 interacts with UV-irradiation-resistance-associated gene (UVRAG) to form core complexes that induce autophagy. While cells with defective autophagy... 
RECOMBINATION | REPAIR | INHIBITION | GENE | INDUCED APOPTOSIS | MULTIDISCIPLINARY SCIENCES | ATM | AUTOPHAGY | LC3 | CYCLE | Gamma Rays | Apoptosis - drug effects | Apoptosis - radiation effects | Autophagy - radiation effects | Microtubule-Associated Proteins - metabolism | Humans | Centrosome - drug effects | Intracellular Signaling Peptides and Proteins - metabolism | Centrosome - radiation effects | Autophagy - drug effects | DNA Breaks, Double-Stranded - radiation effects | Gene Knockdown Techniques | Cell Nucleus - metabolism | DNA Breaks, Double-Stranded - drug effects | Protein Binding - drug effects | Cytoprotection - drug effects | Protein Binding - radiation effects | Membrane Proteins - metabolism | Colorectal Neoplasms - metabolism | Beclin-1 | Rad51 Recombinase - metabolism | Tumor Suppressor Proteins - metabolism | Apoptosis Regulatory Proteins - metabolism | Centrosome - metabolism | Autophagy-Related Protein 5 | Cell Line, Tumor | Fluorouracil - pharmacology | DNA Damage | Tumor Suppressor p53-Binding Protein 1 | Cell Nucleus - drug effects | Colorectal Neoplasms - pathology | Cytoprotection - radiation effects | Prevention | Ionizing radiation | DNA damage | DNA | Colorectal cancer | Genetic aspects | Tubulins | Cancer | Homologous recombination | Colorectal carcinoma | Radiation | Irradiated | Homology | Cytotoxicity | Biology | Kinases | Autophagy | DNA repair | Cancer therapies | Genomic instability | Deletion mutant | Proteins | Tubulin | Clonal deletion | Cell cycle | Deletion | Tumorigenesis | Chromosomes | Deoxyribonucleic acid--DNA | Radiation effects | Stability | U.V. radiation | Tumor cells | Cell division | siRNA | Metabolism | Ultraviolet radiation | Chemotherapy | Cell death | Irradiation | Hypoxia | Radiation damage | Phagocytosis | Tumors | Apoptosis | Index Medicus | Deoxyribonucleic acid
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e65369
Background: MSH3 is a DNA mismatch repair (MMR) gene that undergoes frequent somatic mutation in colorectal cancers (CRCs) with MMR deficiency. MSH3, together... 
MOLECULAR CHARACTERIZATION | P53 STATUS | MULTIDISCIPLINARY SCIENCES | DNA-DAMAGE | DOUBLE-STRAND BREAKS | MICROSATELLITE MUTATOR PHENOTYPE | HOMOLOGOUS RECOMBINATION | ADJUVANT THERAPY | HUMAN COLORECTAL CANCERS | CROSS-LINKS | SOMATIC MUTATIONS | MutL Protein Homolog 1 | Colonic Neoplasms - drug therapy | Humans | Benzofurans - pharmacology | Antineoplastic Agents - therapeutic use | Organoplatinum Compounds - pharmacology | Gene Knockdown Techniques | DNA-Binding Proteins - metabolism | Cell Nucleus - metabolism | MutS Homolog 3 Protein | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Hydroxamic Acids - pharmacology | Camptothecin - analogs & derivatives | Rad51 Recombinase - metabolism | Cell Survival - drug effects | HCT116 Cells | DNA Mismatch Repair - drug effects | Nuclear Proteins - metabolism | Colonic Neoplasms - pathology | Fluorescent Antibody Technique | Histone Deacetylase Inhibitors - pharmacology | Fluorouracil - pharmacology | DNA Damage | Adaptor Proteins, Signal Transducing - metabolism | Cell Nucleus - drug effects | Camptothecin - pharmacology | Drug Screening Assays, Antitumor | Chemotherapy | Ionizing radiation | Colon cancer | Metabolites | DNA damage | Genes | DNA repair | Cancer | Fluorouracil | Drugs | Histone deacetylase | Histone H2A | 5-Fluorouracil | Toxicity | Homologous recombination | Colorectal cancer | Radiation | Cytotoxicity | Homology | Cancer therapies | Proteins | Oxaliplatin | Mismatch repair | Colon | Repair | Deoxyribonucleic acid--DNA | Sensitivity analysis | Cell survival | MLH1 protein | MSH2 protein | Crosslinking | Chromosome 5 | Chromosome 3 | Double-strand break repair | Survival | Cisplatin | Irinotecan | Sensitivity | Inhibitors | Irradiation | Protein expression | Sensitivity enhancement | Mutation | Viability | Apoptosis | Tumors | Deoxyribonucleic acid | DNA
Journal Article
British Journal of Cancer, ISSN 0007-0920, 06/2018, Volume 119, Issue 4, pp. 1 - 5
BACKGROUND: Triplet chemotherapy, with docetaxel-5FU-oxaliplatin (TEFOX), has yielded promising results in patients with advanced and operable gastric... 
PHASE-III TRIAL | CYTOREDUCTIVE SURGERY | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | PERITONEAL CARCINOMATOSIS | ADENOCARCINOMA | OXALIPLATIN | CANCER | DOCETAXEL | JUNCTION | PLUS FLUOROURACIL | Adenocarcinoma | Chemotherapy | Oxaliplatin | Radiation therapy | Patients | Metastases | Gastric cancer
Journal Article